BioMedNewsBreaks

WednesdayAug 16, 2023 11:05 am

BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), is focused on advancing treatments for some of the world’s deadliest diseases. In late 2022, the company announced the award of a U.S. patent for its oncology platform, as well as promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. Scientists at the Fred Hutchinson Cancer Center were also, at that time, conducting studies of the company’s HIV platform with expected positive results. “We continue to prioritize the efficient research, development and commercialization of our promising oncology and HIV pipelines,” said the company’s CEO Dr. Mark Dybul. “Enochian’s…

Continue Reading

TuesdayAug 15, 2023 1:19 pm

BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Committed to Rapid Advancement of Its Proprietary Oncology Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), in late 2022, was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be used to induce life-long remission from some of the world’s deadliest solid tumors. “We are incredibly excited to have been awarded this patent for Enochian’s allogeneic cell and gene therapy cancer treatment platform, especially following promising early study results,” said the company’s CEO Dr. Mark Dybul. “This technology could be transformative for oncology and for treating some of the world’s deadliest cancers, including pancreatic cancer, which has a five-year survival rate of just 5% to…

Continue Reading

TuesdayAug 15, 2023 12:38 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present Phase 1 Data on Lucid-MS at Milan Peer Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that its late breaking abstract about phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for Oct. 11-13, 2023. “We are excited about presenting our phase 1 first-in-human clinical data on Lucid-MS at this peer conference in Milan,” said Andrzej Chruscinski, M.D., Ph.D., VP, clinical and scientific affairs, Lucid Psycheceuticals. “Current…

Continue Reading

MondayAug 14, 2023 2:39 pm

BioMedNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Announces Q2 2023 Results, Strategic Business Review Update

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company today announced financial results for the three months ended June 30, 2023, and provided an update on its business review. “During the past several months, we have focused on expense reduction to extend runway, optimize marketing mix, and support business development efforts. While this streamlining had a modest unfavorable impact on sales during the quarter, we have gained greater conviction that driving consumer awareness is the next…

Continue Reading

MondayAug 14, 2023 2:01 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2024 Financial Report

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer's disease, period cramps (dysmenorrhea), premenstrual syndrome ("PMS") and chronic pain, is reporting on its financial and business results for the first quarter of the 2024 fiscal year, the period ended June 30, 2023. Highlights of the report include a 161% increase in net revenue, which totaled approximately $555,000 compared to $212,000 in the same quarter of 2023; continued momentum in the development of IGC’s phase 3 manufacturing facility located on the West Coast; a $12 million line…

Continue Reading

MondayAug 14, 2023 12:52 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterated upcoming milestones. “We are approaching the most important milestone to date since we launched CNS Pharma. We are just a few months away from reporting topline results from our Berubicin potentially pivotal study interim analysis and, although we do not know what the data looks like at this time, we remain hopeful as we also approach…

Continue Reading

MondayAug 14, 2023 11:47 am

BioMedNewsBreaks — HippoFi Inc. (ORHB) Subsidiary Granted Patent for Advanced Cartilage Regeneration and Arthritis Solutions

HippoFi (OTC: ORHB), formerly ORHub Inc., and its wholly owned subsidiary, PUR Biologics, has received a new patent; according to the announcement, the patent covers advanced cartilage regeneration and arthritis solutions that mark a significant advancement in treating the destructive effects of osteoarthritis and cartilage degeneration. The company stated that this addition to its intellectual property portfolio gives PUR Biologics “exclusive rights to innovative methods and compositions that utilize induced Pluripotent Stem Cells (‘iPSCs’) to produce an advanced extracellular matrix (‘ECM’). . .[heralding] a transformative phase in spine and orthopedic treatments.” The announcement noted that the need for effective cartilage…

Continue Reading

FridayAug 11, 2023 2:46 pm

BioMedNewsBreaks – XSurgical Schedules Webinar to Report Quarter Results, Progress

XSurgical, an artificial intelligence surgical robotics company, is hosting an upcoming webinar to report on the company’s quarterly progress and major achievements. Slated for Aug. 24, 2023, at 9 a.m. PST, the webinar will feature key XSurgical leaders, including cofounder and CEO Dr. Gianluca De Novi, board chair Michele Marzola and board of advisors member Arnon Krongrad. XSurgical is bringing an innovative, unique approach to the surgical robotics industry as it focuses on its mission to democratize surgical robotics by creating a versatile platform accessible to a much wider population worldwide. The company is working to increase the quality and number of…

Continue Reading

FridayAug 11, 2023 2:35 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its financial results for the second quarter ended June 30, 2023; the report also included a business update. Highlights of the report include R&D expenses for the quarter totaled $1.45 million compared with $1.97 million for the same period in 2022; marketing, general and administrative expenses for the quarter reached $1.14 million compared with $1.29 million for the 2022 period; total operating expenses for the quarter amounted to $2.56 million compared with…

Continue Reading

FridayAug 11, 2023 2:26 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Releases Updated Information Regarding SRM Entertainment Spin-Off, Closes on Safety Shot Acquisition

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has released the updated payment date for the distribution of shares of common stock, par value $0.0001 per share, of SRM Entertainment Inc. SRM Entertainment is currently a majority-owned subsidiary of Jupiter Wellness. According to the announcement, the date to effect the spin-off of the SRM business is planned for Aug. 14, 2023; the payment date remains subject to SRM’s Registration Statement on Form S-1 being declared effective by the U.S. Securities and Exchange Commission. “In the event that such registration statement is not declared effective…

Continue Reading